In 2020, the pharmaceutical manufacturing core segment of Fosun Pharma generated revenue of RMB21,880 million. The R&D expenditures in the pharmaceutical manufacturing segment amounted to RMB3,670 million, representing a year-on-year increase of 17.21%. Total R&D expenditures in the pharmaceutical manufacturing segment accounted for 16.77% of the revenue of the pharmaceutical manufacturing segment. In particular, R&D expenses amounted to RMB2,468 million, representing a year-on-year increase of RMB727 million or 41.76%, accounting for 11.28% of the revenue from the pharmaceutical manufacturing segment.
Fosun Pharma has a number of superior products in the fields of metabolism and alimentary system, anti-tumor and immune modulation, anti-infection, central nervous system and cardiovascular system.Han Li Kang (rituximab injection) increased its production scale (2,000L) after approval, recording a revenue of RMB750 million for the year; new products Su Ke Xin (avatrombopag maleate tablets) and Han Qu You (trastuzumab injection), which commenced sales in August 2020, accelerated their access after launch, and actively promoted their inclusion in the national, provincial and municipal medical insurance catalogs, each recording revenues of RMB140 million.